HIV-1 Remission: Accelerating the Path to Permanent HIV-1 Silencing

Area of Science:

• Virology
• Immunology
• Gene Therapy

Background:

• Antiretroviral therapy (ART) controls HIV-1 but cannot eliminate latent reservoirs, leading to viral rebound.
• Inefficient proviral silencing allows persistent transcriptionally active HIV-1, hindering a cure.
• Human endogenous retroviruses (HERVs) provide a model for natural, long-term proviral silencing.

Purpose of the Study:

• To propose a novel
• block-lock-stop
• strategy for achieving durable, antiretroviral-free HIV-1 control.
• To achieve long-term silencing of HIV-1 expression, rendering proviruses irreversibly latent and transcriptionally inactive.
• To explore the transformation of persistent HIV-1 into silent and permanently defective proviruses.

Main Methods:

• Leveraging research on HIV-1 latency mechanisms, latency-reversing agents, and Tat inhibitors.
• Applying expertise in the biology of human endogenous retroviruses (HERVs) to emulate natural silencing.
• Utilizing advanced genome engineering technologies for direct excision of remnant HIV-1.

Main Results:

• The proposed strategy aims to create permanently silenced and defective proviruses.
• This approach emulates and accelerates the natural evolutionary path of HERVs.
• Insights from elite controllers inform the strategy for achieving functional cure.

Conclusions:

• The
• block-lock-stop
• approach offers a novel pathway towards a functional cure for HIV-1.
• Permanent proviral silencing and defectiveness are key to long-term, antiretroviral-free control.
• Integration of latency research, HERV biology, and genome engineering can accelerate HIV-1 cure.